Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Status and phase

Completed

Phase 2

Conditions

Adult Glioblastoma

Adult Giant Cell Glioblastoma

Adult Gliosarcoma

Treatments

Other: questionnaire administration

Other: laboratory biomarker analysis

Procedure: quality-of-life assessment

Drug: gefitinib

Other: pharmacological study

Study type

Interventional

Funder types

NIH

Identifiers

NCT00014170

CDR0000068511

NCI-2012-01855

N0074

U10CA025224 (U.S. NIH Grant/Contract)

NCCTG-N0074

Details and patient eligibility

About

Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme. Phase II trial to study the effectiveness of gefitinib in treating patients who have newly diagnosed glioblastoma multiforme.

Full description

OBJECTIVES:

I. Determine treatment effectiveness of gefitinib, in terms of response rate, time to progression, survival at 52 weeks, progression-free survival at 6 months, and overall survival, in patients with newly diagnosed glioblastoma multiforme.

II. Determine the toxic effects of this drug in these patients. III. Assess fatigue, depression, excessive daytime somnolence, and quality of life in patients treated with this drug.

IV. Assess individual variation in responses, pharmacokinetic parameters, and/or biological correlates due to genetic differences in enzymes involved in transport, metabolism, and/or mechanism of action of this drug in these patients.

V. Determine if the type of epidermal growth factor receptor affects tumor response and outcome in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, before each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.

Patients are followed every 8 weeks until tumor progression and then every 3 months for 5 years and annually for up to 10 years. Patients removed from study treatment for reasons other than disease progression are followed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 92 patients will be accrued for this study within 14 months.

Enrollment

92 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Histologically confirmed newly diagnosed WHO grade IV astrocytoma (glioblastoma multiforme) or gliosarcoma
- No WHO grade III anaplastic astrocytoma, oligodendroglioma, or mixed oligoastrocytoma
Completed standard external beam radiotherapy within the past 2-5 weeks
- No evidence of tumor progression during radiotherapy
Performance status - ECOG 0-2
Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 10.0 g/dL
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
AST no greater than 3 times ULN
Creatinine no greater than 1.5 times ULN
No other active malignancy
No uncontrolled infection
No other severe concurrent disease that would preclude study participation
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No prior chemotherapy (including polifeprosan 20 with carmustine implant) for this tumor
See Disease Characteristics
No prior stereotactic radiosurgery or interstitial brachytherapy
No more than 15 weeks since prior surgery